Zoryve vs Eucrisa: Clinical Decision Algorithm
Use Zoryve (roflumilast) as first-line for plaque psoriasis and seborrheic dermatitis; for atopic dermatitis, Zoryve is preferred over Eucrisa (crisaborole) due to superior potency and recent guideline support.
Disease-Specific Recommendations
For Plaque Psoriasis (Ages ≥6 years)
- Use Zoryve 0.3% cream once daily 1
- Zoryve is FDA-approved specifically for plaque psoriasis, including intertriginous areas 1
- Eucrisa has NO FDA approval for psoriasis—only limited off-label case reports exist 2
- At 8 weeks, 39.1% of patients achieved clear/almost clear skin with Zoryve versus 6.6% with vehicle 3
- This is a non-negotiable choice: Zoryve is the only evidence-based option between these two agents
For Atopic Dermatitis
Ages 6+ years:
- Use Zoryve 0.15% cream once daily 4, 1
- The 2025 AAD guidelines provide a conditional recommendation favoring roflumilast for mild-to-moderate AD 4
- At 4 weeks, significantly more patients achieved IGA 0/1 and EASI-75 with roflumilast versus vehicle 4
- Roflumilast demonstrates greater potency: in vitro IC50 of 0.7 nM versus crisaborole's 0.24 μM—over 300-fold more potent 5
Ages 2-5 years:
- Use Zoryve 0.05% cream once daily 1
- Eucrisa is approved down to age 2, but Zoryve now has specific FDA approval for this age group with appropriate dosing 1
Clinical Context: While both are PDE-4 inhibitors, the 2025 AAD guidelines specifically address roflumilast with evidence-based recommendations 4, whereas crisaborole approval predates these guidelines and lacks the same level of recent high-quality evidence integration.
For Seborrheic Dermatitis
- Use Zoryve 0.3% foam once daily 6, 7, 8
- Zoryve achieved 79.5% IGA success at 8 weeks versus 58.0% with vehicle (p<0.001) 6
- Demonstrates rapid onset—case reports show significant improvement within 24 hours, potentially faster than topical corticosteroids 7
- Long-term data shows 80.4% maintained clear/almost clear status at 52 weeks 8
- Eucrisa has no FDA approval for seborrheic dermatitis—only theoretical off-label potential mentioned 2
Safety Profiles
Zoryve (Roflumilast)
- Most common adverse events: diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%) 1
- Application site pain in 1.0% of patients 1
- Low discontinuation rates similar to vehicle 4, 1
- Contraindicated in moderate-to-severe liver impairment (Child-Pugh B or C) 1
Eucrisa (Crisaborole)
- Primary adverse event: application site burning/stinging
- Generally well-tolerated with limited systemic exposure 9
- No specific contraindications for hepatic impairment
Key Clinical Pitfalls
- Don't use Eucrisa for psoriasis or seborrheic dermatitis—it lacks FDA approval and evidence for these conditions
- Check liver function before prescribing Zoryve—absolute contraindication in moderate-to-severe hepatic impairment 1
- Don't confuse Zoryve concentrations: 0.3% for psoriasis/seborrheic dermatitis, 0.15% for AD ages 6+, 0.05% for AD ages 2-5 1
- Counsel patients about GI side effects with Zoryve—diarrhea and nausea occur in 3.1% and 1.2% respectively 1
Practical Algorithm
Step 1: Identify the diagnosis
- Plaque psoriasis → Zoryve 0.3%
- Seborrheic dermatitis → Zoryve 0.3% foam
- Atopic dermatitis → Proceed to Step 2
Step 2: For atopic dermatitis, assess age
- Ages 2-5 years → Zoryve 0.05%
- Ages 6+ years → Zoryve 0.15%
Step 3: Screen for contraindications
- Moderate-to-severe liver disease present → Consider Eucrisa as alternative
- No hepatic impairment → Proceed with Zoryve
Step 4: Consider Eucrisa only if:
- Atopic dermatitis AND
- Hepatic contraindication to Zoryve OR
- Patient cannot tolerate Zoryve's systemic side effects (GI symptoms)
The evidence strongly favors Zoryve across all three conditions where both agents might theoretically be considered, with the 2025 AAD guidelines specifically endorsing roflumilast for atopic dermatitis 4 and robust FDA approval data supporting its use in all three conditions 1.